Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer’s Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated

Chelsea Ann Stellick (Bedrejo), Andrew Greenshaw, Mike Paulden, Sidney Yap, R Tyler Marshall, Janice Y Kung and Eldon Spackman

PLOS ONE, 2024, vol. 19, issue 9, 1-10

Abstract: Accumulation of amyloid-beta (Aβ) in the brain has been explored as a primary cause of Alzheimer’s Disease (AD). Better known as the amyloid hypothesis, it has been the main target of researchers vying to bring their therapeutic interventions to market despite several failed attempts by predecessors. In June 2021, Aduhelm (Aducanumab) became the first U.S. Food and Drug Administration (FDA) approved treatment for AD based on the amyloid hypothesis in which sparked controversy. This meta-analysis aims to investigate the efficacy of amyloid-beta targeting interventions at all stages of the disease including the prodromal or mild cognitive impairment (MCI) stage compared to placebo. All completed and terminated Phase III trials are assessed to provide a comprehensive overview of interventions targeting amyloid-beta to inform the legitimacy of the amyloid hypothesis.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0307761 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 07761&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0307761

DOI: 10.1371/journal.pone.0307761

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().